Financial Data and Key Metrics Changes - The company reported sales of $135 million for Q2 2025, an increase of 4% from $130 million in Q2 2024 [4] - Adjusted EBITDA expanded by 250 basis points sequentially and 130 basis points year-over-year [2][19] - Adjusted diluted earnings were $0.57 per share, up approximately 30% from Q1 2025 and up 7% from the prior year [5][19] - The adjusted gross margin was 38.7%, an increase of 296 basis points compared to Q2 2024 [18] Business Line Data and Key Metrics Changes - Diversified end market sales increased by 13% year-over-year, accounting for 55% of overall company revenue [4][17] - Medical end market sales were up 8% compared to the same period in 2024, with therapeutic products demand increasing by approximately 60% year-over-year [6][7] - Aerospace and Defense sales rose by 34% year-over-year, with SideQuest revenues contributing $4.5 million [8][17] - Industrial market sales were up 5% sequentially and 6% year-over-year, with bookings up 22% from the prior year [9] Market Data and Key Metrics Changes - Transportation sales were €61 million in Q2 2025, down approximately 6% from the same period last year due to market dynamics in China [10] - The North American light vehicle market is expected to be in the 15 million unit range, while European production is forecasted at 16 million units [13][14] - China volumes are projected to be in the 30 million unit range, with electric vehicle penetration rates softening in some regions [14] Company Strategy and Development Direction - The company is focused on a diversification strategy to enhance growth in medical, industrial, aerospace, and defense markets [2][3] - The integration of the SideQuest business is progressing well, with expectations for stronger sales in the second half of 2025 [8][15] - The company aims to expand its customer base and range of applications in diversified end markets [12] Management's Comments on Operating Environment and Future Outlook - Management noted that the impact of tariffs was minimal in Q2 2025, but they continue to monitor the situation closely [26] - There is cautious optimism regarding the transportation market, with expectations of a bottoming out in China [28] - The company maintains guidance for sales in the range of $520 million to $550 million and adjusted diluted EPS between $2.20 and $2.35 [16] Other Important Information - The company generated $28 million in operating cash flow in Q2 2025, compared to $20 million in Q2 2024 [20] - A total of $26 million has been returned to shareholders through dividends and share buybacks in 2025 [20] Q&A Session Summary Question: Insights on the medical market dynamics - Management indicated that while therapeutics are performing well, there is some softness in diagnostics due to capital spending in Asia and potential tariff impacts [24][25] Question: Impact of tariffs on the company - The impact of tariffs was described as nominal, with ongoing monitoring of the situation [26][27] Question: Transportation market outlook - Management expressed cautious optimism about the transportation market, noting mixed conditions across regions and potential bottoming out in China [28][29] Question: Integration of SideQuest and cost-saving measures - The integration of SideQuest is progressing well, with a strong pipeline of opportunities, and no significant cost-saving measures are currently being implemented [30][32] Question: Acquisition market outlook - The company is focused on advancing diversified end markets and sees potential opportunities for acquisitions within the next twelve months [53][54]